GFR-话题@MedSci

#GFR#

483篇内容 | 2608人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, objectType=article, longId=165891, objectId=11a416589183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a416589183, replyNumber=0, likeNumber=0, createdTime=2019-05-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a416589183, moduleTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a416589183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534419, encodeId=9579153441969, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell Biol Int：MiR-19b-3p通过特异性靶向PTEN调节PDGFRα+肌细胞的成骨分化, objectType=article, longId=165170, objectId=9db51651e051, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9db51651e051, replyNumber=0, likeNumber=0, createdTime=2019-04-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9db51651e051, moduleTitle=Cell Biol Int：MiR-19b-3p通过特异性靶向PTEN调节PDGFRα+肌细胞的成骨分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9db51651e051)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534418, encodeId=eea91534418e0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancer Cell Int：通过重新激活EGFR/PI3K/AKT信号，SCD1有助于EGFR靶向治疗肺癌, objectType=article, longId=165142, objectId=53341651427b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53341651427b, replyNumber=0, likeNumber=14, createdTime=2019-04-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53341651427b, moduleTitle=Cancer Cell Int：通过重新激活EGFR/PI3K/AKT信号，SCD1有助于EGFR靶向治疗肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53341651427b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534417, encodeId=757c153441e7e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益, objectType=article, longId=164707, objectId=c304164e0717, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c304164e0717, replyNumber=0, likeNumber=73, createdTime=2019-04-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c304164e0717, moduleTitle=奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c304164e0717)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534416, encodeId=e16f1534416e8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Rep：膀胱癌中ETV5与FGFR3和Hippo信号途径有关, objectType=article, longId=164570, objectId=02c51645e052, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02c51645e052, replyNumber=0, likeNumber=88, createdTime=2019-04-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02c51645e052, moduleTitle=Sci Rep：膀胱癌中ETV5与FGFR3和Hippo信号途径有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02c51645e052)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534415, encodeId=6e8b153441556, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, objectType=article, longId=164528, objectId=3745164528c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3745164528c3, replyNumber=0, likeNumber=68, createdTime=2019-04-20, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3745164528c3, moduleTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3745164528c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534414, encodeId=500e1534414b7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位, objectType=article, longId=163018, objectId=a01b163018c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a01b163018c7, replyNumber=0, likeNumber=82, createdTime=2019-03-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a01b163018c7, moduleTitle=徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a01b163018c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534413, encodeId=c7281534413b4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR-TKI不良反应管理专家共识, objectType=article, longId=162988, objectId=b029162988bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b029162988bd, replyNumber=0, likeNumber=12, createdTime=2019-03-27, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b029162988bd, moduleTitle=EGFR-TKI不良反应管理专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b029162988bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534412, encodeId=761c1534412d6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Rep：膀胱癌中组合光免疫疗法（PIT）靶向上皮生长因子受体（EGFR）和人类上皮生长因子受体2（HER2）研究, objectType=article, longId=161567, objectId=a15116156e8b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a15116156e8b, replyNumber=0, likeNumber=62, createdTime=2019-03-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a15116156e8b, moduleTitle=Sci Rep：膀胱癌中组合光免疫疗法（PIT）靶向上皮生长因子受体（EGFR）和人类上皮生长因子受体2（HER2）研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a15116156e8b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534411, encodeId=e27c15344113a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象, objectType=article, longId=160819, objectId=e400160819af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e400160819af, replyNumber=0, likeNumber=82, createdTime=2019-02-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e400160819af, moduleTitle=Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e400160819af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534410, encodeId=0ae51534410f7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！, objectType=article, longId=159801, objectId=957315980197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=957315980197, replyNumber=0, likeNumber=64, createdTime=2019-02-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=957315980197, moduleTitle=Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=957315980197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534409, encodeId=7f1815344093d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ARCH PATHOL LAB MED：EGFR，丝裂原活化蛋白激酶和肺癌中磷脂酰肌醇3-激酶途径共存活化突变的临床验证, objectType=article, longId=159570, objectId=54ee1595e0d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54ee1595e0d5, replyNumber=0, likeNumber=51, createdTime=2019-02-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54ee1595e0d5, moduleTitle=ARCH PATHOL LAB MED：EGFR，丝裂原活化蛋白激酶和肺癌中磷脂酰肌醇3-激酶途径共存活化突变的临床验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54ee1595e0d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534408, encodeId=6e6d1534408df, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：MET扩增是EGFR受体突变非小细胞肺癌患者TKI耐药的关键因素, objectType=article, longId=159074, objectId=2e171590e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e171590e4ea, replyNumber=0, likeNumber=61, createdTime=2019-01-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e171590e4ea, moduleTitle=JCO：MET扩增是EGFR受体突变非小细胞肺癌患者TKI耐药的关键因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e171590e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534407, encodeId=7a97153440ede, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=这例EGFR阳性NSCLC患者的治疗，你怎么看？, objectType=article, longId=157658, objectId=a23115e6589e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a23115e6589e, replyNumber=0, likeNumber=72, createdTime=2019-01-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a23115e6589e, moduleTitle=这例EGFR阳性NSCLC患者的治疗，你怎么看？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a23115e6589e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534406, encodeId=96551534406db, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？, objectType=article, longId=156533, objectId=8846156533e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8846156533e5, replyNumber=0, likeNumber=97, createdTime=2018-12-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8846156533e5, moduleTitle=DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8846156533e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534405, encodeId=94551534405bc, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌, objectType=article, longId=156473, objectId=032c1564e304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=032c1564e304, replyNumber=0, likeNumber=65, createdTime=2018-12-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=032c1564e304, moduleTitle=CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=032c1564e304)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534404, encodeId=f3271534404c8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：Osimertinib治疗EGFR突变非小细胞肺癌的耐药机制, objectType=article, longId=156361, objectId=58b8156361b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b8156361b3, replyNumber=0, likeNumber=133, createdTime=2018-12-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b8156361b3, moduleTitle=CLIN CANCER RES：Osimertinib治疗EGFR突变非小细胞肺癌的耐药机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b8156361b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534403, encodeId=1235153440313, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：EGFR突变腺癌转化为非小细胞肺癌和其他神经内分泌肿瘤, objectType=article, longId=156262, objectId=1e611562623b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e611562623b, replyNumber=0, likeNumber=0, createdTime=2018-12-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e611562623b, moduleTitle=JCO：EGFR突变腺癌转化为非小细胞肺癌和其他神经内分泌肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e611562623b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534402, encodeId=62e51534402e6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著, objectType=article, longId=155981, objectId=0cdf1559810c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cdf1559810c, replyNumber=0, likeNumber=74, createdTime=2018-12-19, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cdf1559810c, moduleTitle=韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cdf1559810c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534401, encodeId=b1941534401df, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=韩宝惠教授：EGFR突变晚期非小细胞肺癌之临床热点聚焦, objectType=article, longId=155724, objectId=2237155e2412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2237155e2412, replyNumber=0, likeNumber=69, createdTime=2018-12-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2237155e2412, moduleTitle=韩宝惠教授：EGFR突变晚期非小细胞肺癌之临床热点聚焦, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2237155e2412)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗

2019-05-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell Biol Int：MiR-19b-3p通过特异性靶向PTEN调节PDGFRα+肌细胞的成骨分化

2019-04-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancer Cell Int：通过重新激活EGFR/PI3K/AKT信号，SCD1有助于EGFR靶向治疗肺癌

2019-04-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益

2019-04-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Rep：膀胱癌中ETV5与FGFR3和Hippo信号途径有关

2019-04-20

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处

2019-04-20

liuyiping (审核中...)

前往app查看评论内容

#GFR#

徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位

2019-03-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR-TKI不良反应管理专家共识

2019-03-27

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Rep：膀胱癌中组合光免疫疗法（PIT）靶向上皮生长因子受体（EGFR）和人类上皮生长因子受体2（HER2）研究

2019-03-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象

2019-02-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！

2019-02-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ARCH PATHOL LAB MED：EGFR，丝裂原活化蛋白激酶和肺癌中磷脂酰肌醇3-激酶途径共存活化突变的临床验证

2019-02-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：MET扩增是EGFR受体突变非小细胞肺癌患者TKI耐药的关键因素

2019-01-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

这例EGFR阳性NSCLC患者的治疗，你怎么看？

2019-01-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

DIABETOLOGIA：DPP-4抑制剂利格列汀抗血管生成作用是通过抑制氧诱导视网膜病变小鼠模型中VEGFR信号通路实现的？

2018-12-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌

2018-12-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：Osimertinib治疗EGFR突变非小细胞肺癌的耐药机制

2018-12-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：EGFR突变腺癌转化为非小细胞肺癌和其他神经内分泌肿瘤

2018-12-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著

2018-12-19

liuyiping (审核中...)

前往app查看评论内容

#GFR#

韩宝惠教授：EGFR突变晚期非小细胞肺癌之临床热点聚焦

2018-12-15

科室
- - 订阅+
  - 更多科室
工具
服务